病理性近视脉络膜新生血管：玻璃体内雷珠单抗与贝伐单抗的随机对照试验。

Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.

机构信息

Department of Ophthalmology, University of Rome La Sapienza, Rome, Italy.

出版信息

Am J Ophthalmol. 2010 Mar;149(3):458-64.e1. doi: 10.1016/j.ajo.2009.10.010.

DOI:10.1016/j.ajo.2009.10.010

PMID:20172072

Abstract

PURPOSE

To compare the short-term efficacy and safety of intravitreal ranibizumab versus bevacizumab in treating myopic choroidal neovascularization (CNV).

DESIGN

Prospective, comparative, randomized, interventional study.

METHODS

Thirty-two eyes from 32 patients with myopic CNV were consecutively enrolled and randomly treated, in a 1:1 ratio, with intravitreal ranibizumab (0.5 mg) or bevacizumab (1.25 mg) as needed, after the first injection. ETDRS best-corrected visual acuity (BCVA), foveal center thickness (FCT) on optical coherence tomography (OCT), and fluorescein angiographic findings were examined before and after treatment. Patients were followed up for 6 months.

RESULTS

No statistically significant difference in the BCVA improvement, as well as in the FCT reduction, was found between groups during follow-up (P value at 1, 3, 6 months > .05). Complete resolution of fluorescein leakage was observed in all 16 bevacizumab-treated eyes and in 15 out of 16 (93.7%) ranibizumab-treated eyes. No ocular or systemic adverse effects from treatment were encountered.

CONCLUSION

This randomized clinical study cannot determine a statistically significant difference in anti-VEGF treatment effect between ranibizumab and bevacizumab for the treatment of CNV secondary to pathologic myopia. A larger study is required to determine the relative efficacy and duration of action of these drugs.

摘要

目的

比较玻璃体内雷珠单抗与贝伐单抗治疗近视性脉络膜新生血管（CNV）的短期疗效和安全性。

设计

前瞻性、对比、随机、干预性研究。

方法

连续纳入 32 例（32 只眼）近视性 CNV 患者，按 1:1 比例随机接受玻璃体内雷珠单抗（0.5mg）或贝伐单抗（1.25mg）按需治疗，首次注射后。采用 ETDRS 最佳矫正视力（BCVA）、光学相干断层扫描（OCT）中心凹厚度（FCT）和荧光素血管造影检查评估治疗前后的结果。患者随访 6 个月。